Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Cytyc to Acquire Digene for $553 Million

By Labmedica staff writers
Posted on 26 Feb 2002
In a move to strengthen its position in cervical cancer testing, Cytyc Corp. More...
(Boxborough, MA, USA) has agreed to acquire Digene Corp. (Gaithersburg, MD, USA) for about US$553.7 million in cash and stock.

Cytyc develops and markets sample preparation systems (ThinPrep) and other products for cervical cancer testing that are designed to be more accurate and easier to read. Currently, one in every three US cervical screening tests is a ThinPrep Pap test.

Digene develops and markets DNA and RNA test systems, including the Hybrid Capture test (HC 2) for the human papilloma virus (HPV), which Digene says is the cause of more than 99% of cervical cancer cases. Its HPV test is often used as an adjunct to the Pap test for cervical cancer screening, particularly in ambiguous cases.

"We believe the combined platform of HC 2 technology based upon Digene's substantial portfolio of intellectual property, together with the ThinPrep collection vial, provides tremendous opportunities for molecular testing of a panel of sexually transmitted diseases and other cancer markers,” said Patrick J. Sullivan, CEO and vice chairman of Cytyc.




Related Links:
Cytyc
Digene

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.